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dementia (weighted sample= 16,272) took any antipsychotic medications; 69.7% 
were female and 68.8% were white. The average age was 85 years.  Their physical 
functions were measured by the number activities of daily living (avg. 2.92) and 
number of instrumental activity of daily living (avg. 3.6).  The most frequent diag-
noses were Alzheimer’s disease (78.8%) and vascular dementia (23.2%).  I used the 
Neuropsychiatry Inventory (NPI) for behavior problems (delusions, hallucinations, 
agitation/aggression, depression, apathy, elation, anxiety, disinhibition, irritability/
lability, and aberrant motor behavior).  I evaluated severity of dementia using the 
Clinical Dementia Rating Scale (CDR). I found that older persons with dementia 
are significantly more likely to relocate to the nursing home in 2 years if they were 
severely demented (OR= 1.3, p< .05), or were on antipsychotic medications (OR = 1.0 
p< .05), or were getting older (OR= 0.01, p< .05).  But, those who were living with 
caregiver (OR= -1.8, p< .01), or were Hispanic (OR= -1.4 p< .01) were significantly 
less likely to move to nursing homes.  Alzheimer patients were significantly more 
likely to relocate to nursing home compared to vascular dementia patients (OR= 
-1.4, p< .05). ConClusions: Community-dwelling older persons with dementia are 
more likely to move to nursing home within 2 years if they had to be medicated for 
their behavior problems and were on antipsychotic medications and, the dementia 
is more advanced
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objeCtives: In China, memantine is only reimbursed for severe dementia, while 
approved for moderately severe to severe dementia. The present model assesses 
the clinical and economic outcomes of extending national recommendations for 
memantine to moderate dementia. Methods: A Markov model was developed to 
simulate transition between health states associated with dementia. Three alter-
native strategies - no treatment, memantine prescribed from moderate to severe, 
and memantine prescribed in severe only- were compared over a five-year time 
horizon for a cohort of 1,000 patients with moderate dementia. The proportions of 
severe, dependent or aggressive patients, and caregivers’time, were estimated as 
clinical outcomes. Total costs were estimated and compared as economic outcomes. 
Deterministic sensitivity analyses were conducted to test the robustness of model 
assumptions and parameters estimates. Data inputs were taken from multiple 
sources, including clinical trials and a Delphi panel. The model adopted societal 
perspective with only direct costs considered. Results: After five years, the cohort 
of patients administered memantine from the moderate stage had developed the 
lowest proportions of severe (45%), dependent (52%) and aggressive (7%) patients, 
and necessitated less caregiver’s time (6.7hours/day). In the cohort of patients 
administered memantine in the severe stage only, these estimates were higher 
(54%, 61%, 8% and 8.35 hours/day, respectively). There were higher in patients not 
treated (64%, 77%, 13% and 9.26hours/day). Starting from the third year, memantine 
started in moderate stage incurred the lowest costs. By year five, total costs were 
RMB 182.5, 197.0 and 200.0 million for memantine from moderate, memantine in 
severe only and no treatment respectively. The sensitivity analysis produced com-
parable results. ConClusions: Over five years, memantine consistently demon-
strated higher clinical benefit when administered in moderate to severe patients as 
compared to restricted to severe and showed increasing cost-savings after 2years 
mainly due to the avoided hospitalisations.
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objeCtives: Intravenous Indomethacin and Ibuprofen are treatment of choice for 
pharmacologic closure of patent ductus arteriosus (PDA) in preterm infants accord-
ing to inhibitory effect on cyclooxygenase. However, unavailability of the intrave-
nous formulations in many countries leads to off-label use of oral NSAIDs for PDA 
closure. This study therefore aimed to determine the effectiveness and safety of oral 
NSAIDs compared to their intravenous formulations for PDA closure in preterm and/
or low birth weight infants. Methods: Randomized or quasi-randomized (RCTs) 
and observational studies comparing oral NSAIDs to intravenous Indomethacin or 
Ibuprofen with reported result of closure rate were identified. Fixed and random 
effect models were used for meta-analyses. Heterogeneity test including I2 were 
performed to assess the appropriateness of pooling the data. Results: Fourteen 
studies comparing the effectiveness and safety of oral NSAIDs (Indomethacin, 
Ibuprofen and Sulindac) with intravenous NSAIDs (Indomethacin and Ibuprofen) 
were recruited. For the primary outcome (closure rate), no statistically significant 
difference between oral Ibuprofen and intravenous NSAIDs group [five RCTs of oral 
Ibuprofen versus Intravenous Ibuprofen group; RR = 1.12 (95% CI 0.990, 1.240, I2 
23.1%)] and [four RCTs of oral Ibuprofen versus Intravenous Indomethacin group; 
RR = 1.035 (95% CI 0.755, 1.418, I2 12.7%)]. Results from the observational stud-
ies were also similar to those of RCTs. Two observational studies comparing oral 
Indomethacin and intravenous Indomethacin revealed no statistically significant 
difference (RR = 0.927 [95% CI 0.704, 1.22, I2 0.0%]). There was no significant dif-
ference in adverse outcome between oral and intravenous NSAIDs treatment 
saturation point was reached at 13 in Khyber Pakhtunkhwa province of Pakistan 
from December to February 2014. The interviews were conducted at the hospital 
pharmacy, arrangements for the time and place of interview were made during ini-
tial contacts. Written consent was obtained from the participants prior to the inter-
view. Results: Among the respondents interviewed, nine were male and four female 
hospital pharmacist aged between 25 and 50 years. Thematic content analysis yielded 5 
major themes: (a) Patients reporting (b) Lack of patient counseling (c) Lack of participa-
tion in health awareness programs, (d) Pharmacists reducing the prescribing errors, (e) 
Insufficient number of pharmacists. ConClusions: Findings revealed that hospital 
pharmacist in Pakistan are not actively participating in provision of pharmaceutical 
care services. They are facing significant hurdles for their actively participation in 
patient care, major obstacles is  the unavailability of sufficient number of pharmacist, 
lack of appropriate time for patient counseling and poor relationship between pharma-
cists and other health care providers. Moreover there is a need to explore the concept 
of pharmaceutical care among the other health care providers and general public.
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objeCtives: Paliperidone palmitate long-acting injectable (PP-LAI) is a new once-
monthly atypical antipsychotic for the treatment of schizophrenia. This article 
is to evaluate the efficacy and safety of PP-LAI in the treatment of schizophre-
nia. Methods: Published clinical studies concerning PP-LAI for schizophrenia 
were searched systemically and assessed by Jadad items. RevMan 5.2 software was 
used for data analysis and for calculating the combined outcomes of clinical tri-
als and their 95% Confidence Intervals (CI). Furthermore, sensitive analysis and 
publication bias test were conducted to assess the stability of results from Meta-
analysis. Results: 12 clinical randomized controlled trials including 39 analytic 
sets were selected for Meta-analysis. According to Jadad items, the qualities of 
including researches were high in which the rules of random grouping and balanc-
ing baseline characteristics between groups were conducted rigorously. The inci-
dence of effective cases in PP-LAI group was 1.7 (95%CI: 1.50-1.91) times higher than 
that in placebo group (Z= 8.55, P< 0.01) and equaled to the rate in risperidone group 
(RR= 1, 95%CI: 0.88-1.13). Compared with the control group of placebo (RR= 1.01, 
95%CI: 0.97-1.05) and risperidone (RR= 1.07, 95%CI: 0.98-1.16), PP-LAI seemed to 
be well tolerated, with the same incidence of adverse events. The stability of the 
present Meta-analysis was accepted without any statistical significance found by 
sensitive analysis and publication bias test. ConClusions: Paliperidone palmitate 
has certain efficacy and safety in the treatment of schizophrenia.
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objeCtives: Dementia is an irreversible brain disease that results in progressive 
cognitive impairment and, eventually, inability to carry out the simplest tasks of 
daily living. Currently there exists no cure for this disease. Patients suffering demen-
tia require plenty of care, mainly provided by the families. The objective of this 
study was to assess the time required from the patients’ caregivers according to the 
patient’s health state, and the consequences for the active population in current 
China. Methods: The current Chinese demographic structure was put in balance 
with the need of caregiving time needed by the dementia population. Demographic 
data, proportion of diagnosed and/or treated patients were provided the China 
Alzheimer’s project Memory360. A Markov model was developed to estimate the 
average caregiver’s time needed per patient per day over 5 years, separately for 
treated and not treated patients. Results: Current demographic situation in China 
is rather favourable with 70% of the population aged between 15 and 59 years (com-
pared to 60% in Europe or United States and 65% in Japan). There are approximately 
6 active persons for one elderly. It was demonstrated that over five years, untreated 
patient with dementia requires around 9.3 hours per day compared to 6.7 hours per 
day for a treated patient. It was estimated that there were 10 million patients with 
dementia in China, with only 21.3% among them receiving treatment. More than 
87 million hours per day are needed to take care of Chinese patients with dementia 
for around 910 million working people. ConClusions: In the current situation 
of China, it is estimated that in average one worker over ten will spend one hour 
per day providing care to a patient affected by dementia. Taking into account the 
rapidly aging population, this burden is likely to increase considerably in the future.
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objeCtives: This study examined factors of relocating to nursing homes among 
community-dwelling older persons with dementia. Methods: This retrospective 
study used data from The Aging, Demographics, and Memory Study (ADAMS) to 
assess dementia severity and service use from 2002 to 2004 in the United States. This 
study examined psychotropic medication use among 279 older people diagnosed 
with dementia and used logistic regressions to identify factors associated with 
nursing home relocation among older persons with dementia. Results: Among 
older persons with dementia (weighted sample = 177,843), 9.2 % of persons with 
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nificantly lower all-cause mortality rate (14.4% vs 51.7%, p< 0.001), fewer total hos-
pitalizations (p< 0.001) and fewer hospitalizations due to cardiovascular problems 
(p< 0.001) were observed in patients discharged with statins. LDL-C goal attainment 
of < 100 mg/dL (2.6 mmol/L) resulted in a significant reduction in mortality (10.8% vs 
24.2%, p= 0.001), but not for goal attainment of < 70 mg/dL (1.8 mmol/L). Significant 
difference in survival existed only when LDL-C cut-off values were above 92 mg/dL 
(2.4 mmol/L). ConClusions: This study revealed a J-curve phenomenon in ACS 
patients of Hong Kong. Further research should be conducted to assess the necessity 
of aggressive LDL-C reduction to < 70 mg/dL (1.8 mmol/L).
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objeCtives: The New Cooperative Medical Scheme (NCMS) which aims to reduce 
the risk of catastrophic health spending for rural residents has substantially 
improved health care access and utilization in China. However, cost containment 
and provider incentive remains a huge challenge, which has been particularly acute 
in poorer rural areas, such as the North-west. Over the past years, several coun-
ties in Gansu province have introduced a variety of provider payment reforms, 
shifting from the traditional Fee-for-Service to case-based, global budget  and/
or per-diem  methods. This study provides the first impact evaluation of these 
reforms. Methods: Using a quasi-experimental design, we collected NCMS claims 
data from 2008 to 2013 in three counties. A difference-in-difference analysis is per-
formed to take advantage of the variation in provider payment methods imple-
mented at different years across the counties. We also control for patients’ age, 
gender and diagnosis as well as demographic factor of each county in estimating the 
effects of payment reform on cost (measured by inpatient health care expenditure) 
and quality (measured by readmission rate). In addition to the quantitative analysis, 
we conduct key informant interviews with policymakers, hospital administrators, 
and medical professionals to better understand the design and implementation 
issues involved in the reform process. Results: Preliminary data analysis indicates 
that in one county, the provider payment reform is associated with 9.8% drop in total 
health care expenditure per admission. Length of stay fell by 4.9% as a result too.  
However, other factors such as changes in the demand-side reimbursement rate 
may also influence the outcomes. Differences in local infrastructure and technical 
capacity have led to the same payment method implemented differently at the 
county level. ConClusions: Provider payment reform in rural China can be an 
effective way to control health expenditure. However, more technical guidance on 
designing the right payment is needed for future reforms.
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objeCtives: Single pill combinations (SPC) are associated with improved adherence 
and persistence in hypertensive (HTN) populations. High adherence and persistence 
can provide medical benefit for patients and reduce the total health care utiliza-
tion and costs. This study investigated if Exforge HCT is associated with reduced 
health care utilization and costs during the 12 months follow up period in adult 
hypertensive (HTN) patients adherent to treatment. Methods: A retrospective 
cohort study was conducted including adult (18 yrs. or older) HTN patients covered 
by commercial and Medicare Supplemental insurance in the Truven MarketScan 
database with an HTN diagnosis between October 2009 and December 2011. At 
least two filled prescriptions for Exforge HCT or two periods of minimum 15 days 
of concurrent use of amlodipine, valsartan and hydrochlorothiazide (FC cohort), 
and at least 80% Medication Possession Ratio(MPR) were required. Chi-Square tests 
and independent sample t-tests were used after propensity score matching (PSM) 
(absolute standardized differences (ASM) < 0.1) using demographics, comorbidi-
ties, pre-index HRU, pre-index costs and valsartan initial dose. Results: Adherent 
Exforge HCT patients (N= 6,004) had better outcomes compared to adherent FC 
patients (N= 1,084) in the 12 months follow up period: less all cause hospitalization 
(9.2% vs 16.6%, p< 0.05; Mean 0.1 vs 0.2, p< 0.0001), less all cause ER visits(19.0% vs 
29.3%, p< 0.05; Mean 0.3 vs 0.6, p< 0.0001), less HTN specific ER visits(7.0% vs 12.0%, 
p< 0.05; Mean 0.1 vs 0.2, p< 0.0001), less total medical service cost(7247$ vs $10370, 
p< 0.0001), less total prescription drug costs(3926$ vs $5350, p< 0.0001) and less total 
health care costs($11173 vs $15720, p< 0.0001). After applied PSM, adherent Exforge 
HCT patients still had lower proportion of all cause hospitalization, all cause ER 
visit and less number of all prescriptions, p< 0.05. ConClusions: Real-world data 
indicate that Exforge HCT is associated with less health care utilization and costs 
compared to amlodipine/valsartan/hydrochlorothiazide FC among patients with 
adherent treatment of HTN.
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objeCtives: Generic entry of pharmaceuticals in Australia triggers a price reduc-
tion of 16%, followed by further reductions via a process called ‘Price Disclosure’ 
(PD).  Significant price reductions for standard of care (SOC) derived through PD 
groups. ConClusions: No statistically significant difference in the effectiveness 
of oral Ibuprofen and oral Indomethacin compared to the intravenous NSAIDs with 
similar adverse outcome were observed. Oral formulations of Indomethacin and 
Ibuprofen might be considered as an alternative pharmacologic closure in PDA 
treatment for the NICU settings where intravenous NSAIDs is unavailable.
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objeCtives: To evaluate the management of ischaemic stroke (IS) patients enrolled 
in the Japan Stroke Databank (JSD) from 2000 to 2007. Methods: JSD is an obser-
vational registry of patients who experienced a stroke event, collecting patient 
information provided by over 80 Japanese hospital departments. Data included 
demographics, time to admission, medical history, stroke type diagnosis, imaging, 
treatment,  Japan Stroke Scale (JSS), NIH Stroke Scale (NIHSS) and the modified 
Rankin Scale (m-RS). Logistic regression model was used to identify predictors of 
m-RS 0-1 at discharge. Results: Of the 47,782 stroke patients, when excluding for 
transient ischemic attack (TIA) cases, 15,282 (32%) were ischaemic stroke cases with 
NIHSS evaluation at hospitalization and at discharge and with m-RS assessment 
at discharge. Average age was 69.7 years (±10.6) and 64% were males. Patients who 
were admitted to hospital at a later time window from onset had a lower m-RS score 
(0-1) at admission (12%, 13%, 15% and 17% for patients admitted at 0-3, 3-4.5, 4.5-8 
and 8-24 hours , respectively). However, patients admitted at later time-windows 
had worse disability at discharge (within patients admitted with m-RS 0-1, 53% vs. 
48% had m-RS 0 at discharge depending if admitted before or after 3 hours after 
onset). 57% of patients arrived after 3 hours and only 5.8% received thrombolytic 
treatment (2.1% received alteplase and the remaining received urokinase). Non-
significant severity at baseline and alteplase with edaravone lowered the odds of 
severity at discharge. ConClusions: This study demonstrates that despite the 
availabilities of therapies for acute ischemic stroke there is still a high unmet need 
to reduce severity at discharge for these patients as only 5.8 % of patients receive 
thrombolytic therapy.
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objeCtives: As the international guidance for lipid control has evolved, the 
National Health Insurance Administration (NHIA) in Taiwan was requested to 
modify the current reimbursement criteria for initiation of lipid-lowering treatment. 
The study aims to evaluate the cost-effectiveness and the budget impact of the 
newly proposed reimbursement criteria on lipid-lowering drug from the NHIA’s 
viewpoint with a focus on the change of statins usage. Methods: In the new cri-
teria, the cut-off points of low-density lipoprotein cholesterol (LDL-C) and total 
cholesterol for initiating lipid-lowering therapy for patients having diabetes or previ-
ous heart diseases (high risk group) have been lowered. A Markov decision model 
was constructed to examine the cost-effectiveness of the new criteria compared 
with the original ones. The efficacy of statins on coronary heart diseases (CHD) 
and stroke was obtained from the literature. The numbers of subjects who may be 
affected by these criteria changes and the LDL-C specific disease transition prob-
abilities were obtained from a population-based survey conducted by the Taiwan 
Health Promotion Administration (HPA). Medical costs were derived from the NHI 
data. Both costs and health outcomes were discounted at 3%. The corresponding 
financial impact on NHI expenditure was also estimated. Results: If the new crite-
ria are applied, the number of subjects who fulfill the reimbursement criteria in the 
high risk group will be almost twice as many as before. This would lead to an great 
increase in the NHI expenditures for statins and monitoring costs, however, this 
could be offset by the treatment cost saved from the averted CHD and stroke cases. 
Therefore, the new criteria are a dominant strategy compared with the original cri-
teria. ConClusions: Although the newly proposed reimbursement criteria would 
lead to an increase in drug expenditure of NHIA, it is expected to be a cost-saving 
strategy after taking into account the health benefit on preventing CHD and stroke.
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objeCtives: The current study primarily aimed to assess the current prescribing 
pattern of lipid-lowering agents and the percentage of LDL-C goal attainment in 
myocardial infarction (MI) patients in local practice, and to evaluate clinical out-
comes of patients stratified by prescription of statins and by LDL-C level attained 
after discharge. Methods: We retrospectively reviewed 696 hospitalized patients 
in the local ACS registry of Prince of Wales Hospital during 1 January 2008 to 31 
December 2009 with data retrieved using computerized clinical records of all 
patients. Results: Among the 402 MI patients included, 104 (25.9%) were not pre-
scribed with statins at discharge. Percutaneous coronary intervention (PCI) per-
formed or planned during hospitalization (OR: 0.324, p= 0.001) and latest LDL-C level 
before discharge (OR: 0.221 for an increment of 1 mmol/L, p= 0.009) were significant 
independent predictors of the absence of statin prescriptions at discharge. A sig-
